Octapharma - Articles and news items

FDA approves Octapharma’s Nuwiq for haemophilia A

Industry news / 16 September 2015 / Victoria White

Nuwiq is the first B-domain deleted recombinant Factor VIII derived from a human cell-line designed for the treatment of patients with haemophilia A…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+